Terms: = Skin cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
60 results:
1. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.
De Carli A; Kapelyukh Y; Kursawe J; Chaplain MAJ; Wolf CR; Hamis S
NPJ Syst Biol Appl; 2024 May; 10(1):51. PubMed ID: 38750040
[TBL] [Abstract] [Full Text] [Related]
2. Hyaluronic acid-based injectable formulation developed to mitigate metastasis and radiation-induced skin fibrosis in breast cancer treatment.
Wang YC; Shueng PW; Hu CY; Tung FI; Chen MH; Liu TY
Carbohydr Polym; 2024 Jul; 336():122136. PubMed ID: 38670762
[TBL] [Abstract] [Full Text] [Related]
3. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract] [Full Text] [Related]
4. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract] [Full Text] [Related]
5. Stereotactic Radiosurgery and Radiotherapy for Vestibular schwannoma in nf2-Related schwannomatosis.
Shrivastava M; Emmanouil B; Mathew R; Halliday D; Parry A; Halliday J; Mackeith S
Laryngoscope; 2024 May; 134(5):2364-2371. PubMed ID: 37983868
[TBL] [Abstract] [Full Text] [Related]
6. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract] [Full Text] [Related]
7. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract] [Full Text] [Related]
8. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
[TBL] [Abstract] [Full Text] [Related]
9. schwannomatosis: a Realm Reborn: year one.
Planet M; Kalamarides M; Peyre M
Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
[TBL] [Abstract] [Full Text] [Related]
10. schisandrin B Inhibits Cell Viability and Malignant Progression of Melanoma Cells
Chen J; Zhang L; Pu Y; Chen Y; Li Y; Pan X; Chen J
Anticancer Agents Med Chem; 2023; 23(15):1765-1773. PubMed ID: 37622448
[TBL] [Abstract] [Full Text] [Related]
11. CP-GEP (merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Quattrocchi E; Meves ES; Meves A
Ital J Dermatol Venerol; 2023 Aug; 158(4):292-301. PubMed ID: 37539500
[TBL] [Abstract] [Full Text] [Related]
12. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
[TBL] [Abstract] [Full Text] [Related]
13. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract] [Full Text] [Related]
14. Targeted Therapies in the treatment of Vestibular schwannomas: Current State and New Horizons.
Welling DB
Otolaryngol Clin North Am; 2023 Jun; 56(3):543-556. PubMed ID: 37024334
[TBL] [Abstract] [Full Text] [Related]
15. Advances in Targeted Therapy for Neurofibromatosis Type 2 (nf2)-Associated Vestibular schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract] [Full Text] [Related]
16. Endophytic Fungus of Achyrocline satureioides: Molecular Identification, Chemical Characterization, and Cytotoxic Evaluation of its Metabolites in Human Melanoma cell line.
Pedra NS; Canuto KM; de Queiroz Souza AS; Ribeiro PRV; Bona NP; Ramos-Sobrinho R; de Souza PO; Spanevello RM; Braganhol E
Appl Biochem Biotechnol; 2023 Jul; 195(7):4011-4035. PubMed ID: 36652091
[TBL] [Abstract] [Full Text] [Related]
17. Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization.
Gugel I; Grimm F; Tatagiba M; Schuhmann MU; Zipfel J
J Neurooncol; 2022 Sep; 159(2):271-279. PubMed ID: 35771312
[TBL] [Abstract] [Full Text] [Related]
18. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract] [Full Text] [Related]
19. Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies.
Sadurní MB; Meves A
Mod Pathol; 2022 Nov; 35(11):1509-1514. PubMed ID: 35654998
[TBL] [Abstract] [Full Text] [Related]
20. Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
Burns R; Niendorf K; Steinberg K; Mueller A; Ly I; Jordan JT; Plotkin SR; Hicks SR
Am J Med Genet A; 2022 Aug; 188(8):2413-2420. PubMed ID: 35638454
[TBL] [Abstract] [Full Text] [Related]
[Next]
